Free Newsletter
Researchers call for wide release of drug safety data
A group of researchers in Boston has taken the FDA to task for what it says is a set of policies that leaves drug safety data hidden in shrouds when it should be widely publicized. They called on the agency to create a new process that would push data out into the public so that analysts can review the data and help physicians determine the safest way to prescribe drugs. Safety data can be released on the FDA's website, they say, while proprietary chemical data on composition and efficacy can be kept secret to protect a drug developer's IP rights.
"Balanced against the need to protect companies' investments in drug development, however, is the risk that withholding this information can frustrate evaluation of drug safety," the authors wrote.
- read the report on the safety initiative from The Boston Globe
Related Articles:
Critics slam FDA on drug safety. Report
FDA offers safety reforms to skeptical lawmakers. Report
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage


